7Baggers
 Protara to present interim phase 2 TARA-002 bladder cancer data at SUO  Investing.com Mon, 17 Nov 2025 13:10:53 GMT
 Protara Therapeutics to Present New Interim Data from Phase  GlobeNewswire Mon, 17 Nov 2025 13:00:00 GMT
 Published on: 2025-11-15 19:28:04  newser.com Sun, 16 Nov 2025 01:28:04 GMT
 Protara Therapeutics Reports Q3 2025 Financial Results  TipRanks Wed, 12 Nov 2025 04:07:47 GMT
 Protara announces proposed offering of common stock  MSN Tue, 11 Nov 2025 16:38:19 GMT
 Protara Therapeutics: Q3 Earnings Snapshot  New Haven Register Tue, 11 Nov 2025 11:07:20 GMT
 Protara Therapeutics: Q3 Earnings Snapshot  CTPost Mon, 10 Nov 2025 19:34:36 GMT
 Protara Therapeutics Stays Confident Despite Rising Losses  Finimize Mon, 10 Nov 2025 14:44:15 GMT
 Protara Therapeutics reports Q3 EPS (31c), consensus (38c)  TipRanks Mon, 10 Nov 2025 13:12:11 GMT
 Protara Therapeutics sees cash runway into mid-2027  TipRanks Mon, 10 Nov 2025 13:12:11 GMT
 Protara Therapeutics Q3 net loss widens  TradingView Mon, 10 Nov 2025 13:11:05 GMT
 published on: 2025-11-06 01:59:52  newser.com Thu, 06 Nov 2025 07:59:52 GMT
 published on: 2025-11-06 01:09:45  newser.com Thu, 06 Nov 2025 07:09:45 GMT
 published on: 2025-11-04 00:31:20  newser.com Tue, 04 Nov 2025 06:31:20 GMT

Protara Therapeutics, Inc
(NASDAQ:TARA) 

TARA stock logo

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformation...

CEO: Jesse Shefferman  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends